Praxis Precision Medicines Says US FDA Extends Review Period for New Drug Application for Relutrigine

NDA FilingRelutrigineNegative

AI Analysis

Summary

Praxis Precision Medicines announced that the US FDA has extended the review period for its new drug application for Relutrigine. The extension indicates a delay in the regulatory timeline for this candidate.

Outcome Details

FDA extended review period

Importance:6/10

Sentiment:

-0.30

FDANDAreview extensionregulatory

Related Companies

$PRAX

Read the original article

Published by yahoo_finance on June 29, 2026 9:06 PM

Read Original